

**Table S1.** Demographics and clinical features of 453 study participants with inflammatory bowel disease (IBD) stratified according to Glucose-6-phosphate dehydrogenase status.

<b>Variables</b>	<b>G6PD <sup>1</sup> normal (n=375)</b>	<b>G6PD <sup>1</sup> deficiency (n=78)</b>
<i>Sex, n (%)</i>		
Female	208 (55.5)	52 (66.7)
Male	167 (44.5)	26 (33.3)
<i>Age (mean, years)</i>	52.4 ± 16.4	50.9 ± 16.6
<i>Age distribution, n (%)</i>		
< 30	39 (10.4)	9 (11.5)
30 - 39	53 (14.1)	14 (17.9)
40 - 49	62 (16.5)	11 (14.1)
50 - 59	88 (23.5)	18 (23.1)
60 - 69	75 (20.0)	14 (17.9)
70 - 79	45 (12.0)	10 (12.8)
≥ 80	13 (3.5)	2 (2.6)
<i>Body mass index, n (%)</i>		
< 25 kg/m <sup>2</sup>	258 (68.8)	45 (57.7)
25 – 29 kg/m <sup>2</sup>	92 (24.5)	25 (32.1)
≥ 30 kg/m <sup>2</sup>	25 (6.7)	8 (10.3)
<i>Cigarette smoke, n (%)</i>		
No	233 (56.8)	53 (67.9)
Former smoker	121 (32.3)	19 (24.4)
Current smoker	41 (10.9)	6 (7.7)
<i>Treatment#, n (%)</i>		
Topical	26 (6.9)	13 (16.6)
Mesalamine per os	247 (65.8)	47 (60.3)
Immunomodulators	61 (16.2)	20 (25.6)
Biologic	54 (14.4)	11 (14.1)
<i>Disease duration, months (%)</i>		
6 – 9	95 (25.3)	22 (28.2)
10 – 19	238 (63.5)	47 (60.3)
20 – 29	34 (9.1)	5 (6.4)
≥ 30	8 (2.1)	4 (5.1)
<i>IBD type, n (%)</i>		
Crohn's	81 (21.6)	30 (38.5)
Ulcerative colitis	294 (78.4)	48 (61.5)
<i>IBD localization (%)</i>		
Distal proctitis	11 (2.9)	1 (1.3)
Ulcerative left colitis	150 (40.0)	37 (47.4)
Pancolitis	123 (32.8)	20 (25.6)
Ileocolic Crohn's	61 (16.3)	19 (24.4)
Colic Crohn's	16 (4.3)	0 (0.0)
Crohn's with fistulae	14 (3.7)	1 (1.3)

<sup>1</sup> Glucose-6-phosphate dehydrogenase; # Drugs were used in different combinations

**Table S2.** Side effects complained by patients with inflammatory bowel disease treated with oral mesalamine as monotherapy according to the G6PD Status

Side effects	G6PD <sup>1</sup> Normal (n=101)	G6PD Deficiency (n=22)
Dispepsia	3	1
Nausea	2	1
Abdominal pain	2	1
Abdominal discomfort	1	0
Abdominal bloating	1	0
Headache	1	0
Constipation	1	0
Pruritus	1	0

<sup>1</sup> Glucose-6-phosphate dehydrogenase

**Table S3.** Markers of hemolytic anemia among 158 patients with inflammatory bowel disease according to oral mesalamine formulation, oral budesonide and glucose-6-phosphate dehydrogenase status.

Variables (normal range)	Multimatrix		Delayed release enteric-coated tablet pH dependent		Controlled release capsule Time reales		Oral Budesonide	
	G6PD normal (n=46)	G6PD deficiency (n=10)	G6PD normal (n=31)	G6PD deficiency (n=7)	G6PD normal (n=25)	G6PD deficiency (n=3)	G6PD normal (n=7)	G6PD deficiency (n=4)
Hemoglobin <sup>†</sup> (g/dL)	14.0 ± 1.2	13.2 ± 1.1	14.3 ± 1.6	12.2 ± 0.8 *	13.6 ± 0.8	13.5 ± 0.4	14.1 ± 0.9	12.3 ± 1.0**
Reticulocytes (0.5-2.5%)	1.21 ± 0.34	1.67 ± 0.75 *	1.29 ± 0.46	2.00 ± 1.13	1.42 ± 0.71	1.10 ± 0.14	1.29 ± 0.59	1.76 ± 0.94
Unconjugated bilirubin (0.20-0.70 g/dL)	0.50 ± 0.49	0.53 ± 0.22	0.46 ± 0.22	0.37 ± 0.04	0.44 ± 0.10	0.94 ± 0.65 *	0.52 ± 0.21	0.63 ± 0.45
Serum iron (50-170 µg/dL)	73.7 ± 27.5	77.4 ± 22.4	89.6 ± 35.9	75.3 ± 18.9	97.3 ± 30.2	55.0 ± 14.1	86.1 ± 28.0	72.9 ± 23.2
Ferritine (8-252 µg/mL)	101.2 ± 54.9	101.3 ± 38.8	106.4 ± 85.5	112.7 ± 23.7	122.7 ± 134.4	100.1 ± 94.5	93.3 ± 62.1	100.1 ± 38.1
Haptoglobin (30-200 mg/dL)	171.4 ± 80.6	197.8 ± 92.7	178.8 ± 55.7	147.3 ± 22.5	130.3 ± 54.2	95.0 ± 7.0	139.2 ± 67.9	120.8 ± 28.1
Lactate dehydrogenase (125-220 U/L)	200.6 ± 51.3	193.2 ± 29.6	123.7 ± 31.3	173.2 ± 37.8 *	179.0 ± 1.41	213.6 ± 136.1	168.3 ± 24.1	187.5 ± 24.1

\* p&lt;0.05; \*\* p&lt;0.001